

PU3318USw

#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: P.L. Feldman, et al.

Serial No.: 09/980,680

Examiner: B. Coleman

Filing Date: 31 Oct 2001

Art Unit: 1624

For: SHORT-ACTING BENZODIAZEPINES

Assistant Commissioner of Patents
Washington, D.C. 20231RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Responsive to the Office Action mailed 16 May 2003, please reconsider the instant application in view of the following election.

Claims 1-17, 19-20, 24-26, and 28-37 are pending. All claims are subject to restriction requirement between Examiner's groups I-IV. Applicants hereby elect the claims of the Examiner's group I, claims 1-14, 24, 25, 28, 29 and 32-35 drawn to compounds, compositions and methods of use of the compounds of Formula (I) where Formula (I) is a benzodiazepine ring, for prosecution on the merits. Applicants will await an indication of allowability before amending the claims to remove the non-elected subject matter.



Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222 to discuss this case further, if desired.

Date: June 06, 2003
GlaxoSmithKline, Inc.
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709
ph: 919 483-8222
fax: 919 483-7988

Respectfully submitted,



Lorie Ann Morgan, Esq.
Reg. No. 38,181

| TRANSMITTAL LETTER (General - Patent Pending) | | | Docket No. PU3318USW |
|--|--------------------------------|----------------------------|--------------------------------|
| In Re Application Of: Feldman et al. | | | |
| Serial No. 09/980,680 | Filing Date 10/31/01 | Examiner Coleman | Group Art Unit 1624 |
| Title: SHORT-ACTING BENZODIAZEPINES | | | |
| <p style="text-align: center;"><u>TO THE COMMISSIONER FOR PATENTS:</u></p> <p>Transmitted herewith is:</p> <p style="padding-left: 40px;">Response to Restriction Requirement</p> <p>in the above identified application.</p> <p><input checked="" type="checkbox"/> No additional fee is required.</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.</p> <p style="padding-left: 80px;"><input type="checkbox"/> Charge the amount of _____</p> <p style="padding-left: 80px;"><input checked="" type="checkbox"/> Credit any overpayment.</p> <p style="padding-left: 80px;"><input checked="" type="checkbox"/> Charge any additional fee required.</p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"><div style="text-align: center;"> _____ <i>Signature</i></div><div style="text-align: right;">Dated: 6/9/03</div></div> <p>Lorie Ann Morgan, Reg. No. 38,181</p> <div style="text-align: center; margin-top: 20px;"> 23347 PATENT TRADEMARK OFFICE</div> | | | |
| <div style="border: 1px solid black; padding: 5px;"><p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 39 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p><p style="text-align: center; margin-top: 10px;"><i>Signature of Person Mailing Correspondence</i></p><p style="text-align: center; margin-top: 10px;">_____ <i>Typed or Printed Name of Person Mailing Correspondence</i></p></div> | | | |

P16AREV01

FAX**To** USPTO; Examiner B. Coleman, Art Unit 1624**Company****Fax** 703-872-9306**From** Valerie L. Phillips**Tel** 919-483-8223 **Fax** 919-483-5730**E-mail** Vlp47157@gsk.com**Date** June 9th, 2003 **Pages including cover** 3**Subject** Response to Restriction Requirement

Serial No.: 09/980,880
Filing Date: October 31, 2001
Applicant: Feldman et al.
Title: Short-Acting Benzodiazepines

Attached:
Certificate of transmission via facsimile
Response to Restriction Requirement
Transmittal Letter

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-872-9306) on June 9, 2003.

Valerie L. Phillips
Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.



GlaxoSmithKline

Glaxo Wellcome Inc.
PO Box 13388
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

FAX RECEIVED

JUN 10 2003

GROUP 1600**OFFICIAL**